Article,

Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban

, , , , , , , , , and .
Science, 299 (5611): 1410-3 (February 2003)Schmitt, Joachim P Kamisago, Mitsuhiro Asahi, Michio Li, Guo Hua Ahmad, Ferhaan Mende, Ulrike Kranias, Evangelia G MacLennan, David H Seidman, J G Seidman, Christine E Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. United States Science (New York, N.Y.) Science. 2003 Feb 28;299(5611):1410-3..

Abstract

Molecular etiologies of heart failure, an emerging cardiovascular epidemic affecting 4.7 million Americans and costing 17.8 billion health-care dollars annually, remain poorly understood. Here we report that an inherited human dilated cardiomyopathy with refractory congestive heart failure is caused by a dominant Arg --> Cys missense mutation at residue 9 (R9C) in phospholamban (PLN), a transmembrane phosphoprotein that inhibits the cardiac sarcoplasmic reticular Ca2+-adenosine triphosphatase (SERCA2a) pump. Transgenic PLN(R9C) mice recapitulated human heart failure with premature death. Cellular and biochemical studies revealed that, unlike wild-type PLN, PLN(R9C) did not directly inhibit SERCA2a. Rather, PLN(R9C) trapped protein kinase A (PKA), which blocked PKA-mediated phosphorylation of wild-type PLN and in turn delayed decay of calcium transients in myocytes. These results indicate that myocellular calcium dysregulation can initiate human heart failure-a finding that may lead to therapeutic opportunities.

Tags

Users

  • @pharmawuerz

Comments and Reviews